R&D channel feed – Endpoints News

R&D channel feed

Wrestling with setbacks, Celgene adds $65M discovery alliance with Evotec to beef up on new cancer drugs

8 years ago

Nabriva goes 2 for 2 in Phase III antibiotic program, scoring on a key catalyst -- but shares plunge on safety worries

8 years ago

Roche adds a stellar round of pivotal data on Hemlibra, looking to expand its market for a potential mega-blockbuster

8 years ago

Another cheap, old drug is being freshened up for brand pricing in the US — and shares soar, briefly

8 years ago

Agile bristles after FDA's third snub, promising a fight for its contraceptive

8 years ago

Syndax is hit with a setback during the ASCO preview round as lead drug flops in mid-stage study

8 years ago

J&J axes its big BACE program in asymptomatic Alzheimer's patients as the drumbeat of PhIII failures rolls on

8 years ago

Will Shire's top R&D talent bolt now that Takeda has struck a merger agreement?

8 years ago

Citing significant progress on a cure for diabetes, Novo Nordisk beefs up its stem cell pipeline with new collaborations

8 years ago

The top winners and losers on ASCO abstract night: Loxo, Blueprint, Jounce, Merck KGaA and more

8 years ago

Gilead fortifies its pioneering cell therapy status, expanding into three new facilities and teaming with NCI

8 years ago

Eli Lilly touts some mixed PhIII results for cluster headaches as Amgen, Novartis prep a market-busting move in migraine

8 years ago

Troubled aTyr axes 30% of its staff as it wipes a preclinical slate clean

8 years ago

Bluebird bio dives deeper into its TCR alliance with Medigene, adding $500M in milestones and 2 new targets

8 years ago

AstraZeneca's star respiratory drug runs into another wall with COPD, but it's not giving up — yet

8 years ago

Eight years after Eli Lilly dumped it, an upstart biotech has nabbed teplizumab and filed a $56M IPO to back a PhIII comeback

8 years ago

Little vTv once again circles subgroup number, struggling to find something good to say about failed Alzheimer's drug

8 years ago

Roche's big PhIII Tecentriq/Cotellic combo study for colon cancer fails, damaging Exelixis shares

8 years ago

Lipocine shares tumble (again) after the FDA shows another testosterone therapy the door

8 years ago

Can you cut $600M in R&D costs without slash-and-burn tactics? Andy Plump aims to show us how

8 years ago

Daiichi scores in PhIII study of AML drug, beating chemo and building its case for worldwide approvals

8 years ago

Poised to launch its first marketing effort, Alnylam makes a big leap into CNS diseases and Alzheimer's

8 years ago

With hits and misses in first pivotal trials, J&J confidently maps a path to the FDA with its major depression med esketamine

8 years ago

Celgene works to calm down anxious investors, promising to re-file ozanimod at the FDA in early 2019

8 years ago

First page Previous page 272 273 274275276 277 278 Next page Last page